AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (49)

Latest Posts

About This Stock More About This Stock
Teva Rallies After Finding Experienced CEO, But Not Astra's, To Take Over
Article By: The Fly
Monday, September 11, 2017 2:22 PM EDT
Shares of Teva Pharmaceutical surged in morning trading after naming a permanent chief executive officer, ending a monthslong search for a new chief. The new CEO brings 30 years of global pharmaceutical and healthcare experience
In this article: TEVA Also: HLUYY, NVO, AZN
Read
E Brokerage Problems Again
Article By: Vivian Lewis
Monday, September 4, 2017 7:33 AM EDT
Company news and problems which affect brokerage firms.
In this article: ALV, AZN, BBVA, BNS, BNY, GSK, NVS, SLB, VALE, BAESY, FCGYF, OROCF, RHHBY, STDAF, MAGS, DRYS, INFY, TEVA
Read
Biotech Digest – URGN Receives Fast Track Designation, MDVX Receives Australian Approval, AZN Inks A New Deal
Article By: KKD Healthcare Analytics
Wednesday, August 30, 2017 12:45 PM EDT
UroGen Pharma announced that the FDA has designated its MitoGel for Fast Track review for the treatment of patients with low-grade upper urinary tract urothelial carcinoma. AstraZeneca inked a new deal with Takeda Pharmaceutical.
In this article: AZN, RNN, SGEN, ABEO, TRHC, URGN, MDVX, MBRX
Read
Biotech Digest – GMED Receives Clearance, BIOC Inks New Collaboration, PFE Receives Approval
Article By: KKD Healthcare Analytics
Friday, August 18, 2017 2:03 PM EDT
Globus Medical Inc. stock perked up as the company announced receiving the 510 (k) clearance from the FDA for Excelsius GPS. AstraZeneca announced receiving the FDA approval for its Lynparzaa. Pfizer has FDA approval for its Besponsa.
In this article: AZN, HUM, OPK, PFE, BIOC, FLDM, OMER, AMGN, MYGN, TTPH, GMED, HRTX, IOVA
Read
Can Pfizer Bank On New Immunotherapy Bavencio For Growth?
Article By: Zacks Investment Research
Thursday, August 17, 2017 12:59 PM EDT
As demand for immuno-oncology drugs and their combinations rises, Pfizer, Inc.’s newly approved immunotherapy, Bavencio, is being considered a significant top-line driver for this New York-based pharma giant.
In this article: PFE Also: AZN, MRK, NVS
Read

PARTNER HEADLINES

Latest Tweets for $AZN

No tweets yet!